The two basic mainstays of gastrointestinal stromal tumors (GIST) treatment are surgery and imatinib, a selective tyrosine kinase inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST. Response to imatinib mainly depends from KIT and PDGFRα mutational status. Nevertheless, some patients with a potentially responsive genotype do not respond, and others develop a pattern of resistance to imatinib which is not associated with secondary mutations. This emphasizes the presence of mechanisms of resistance other than the receptor-related genotype, and the need of biological predictors to select the optimal therapeutic strategy, particularly now that other potent inhibitors are available. We investigated a panel of 31 polymorphisms in 11 genes, potentially associated with the pharmacogenetics of imatinib, in a group of 54 unresectable/metastatic GISTs treated with imatinib 400 mg daily as first line therapy. Included in this analysis were polymorphisms in the transporters’ family SLC22, SLCO, ABC, and in the metabolizing genes CYP -3A4 and -3A5. Time to progression was significantly improved in presence of the C allele in SLC22A4 (OCTN1 rs1050152), and the two minor alleles (G) in SLC22A5 (OCTN2 rs2631367 and rs2631372). Importantly, multivariate analysis, adjusting for age, gender, KIT/PDGFRα mutational status, and tumour size, revealed that all the three genotypes maintained independent predictive significance. In conclusion, in this study we showed that SLC22A4 and SLC22A5 genotypes may be an important predictor of time to progression in GIST patients receiving imatinib therapy. Further investigations are required in an attempt to further personalize GIST therapy.
Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, et al. (2013). Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable Gastrointestinal stromal tumours treated with imatinib therapy. PHARMACOLOGICAL RESEARCH, 68(1), 1-6 [10.1016/j.phrs.2012.10.015].
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable Gastrointestinal stromal tumours treated with imatinib therapy
ANGELINI, SABRINA;PANTALEO, MARIA ABBONDANZA;RAVEGNINI, GLORIA;CAVRINI, GIULIA;NANNINI, MARGHERITA;SAPONARA, MARISTELLA;HRELIA, PATRIZIA;CANTELLI FORTI, GIORGIO;BIASCO, GUIDO
2013
Abstract
The two basic mainstays of gastrointestinal stromal tumors (GIST) treatment are surgery and imatinib, a selective tyrosine kinase inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST. Response to imatinib mainly depends from KIT and PDGFRα mutational status. Nevertheless, some patients with a potentially responsive genotype do not respond, and others develop a pattern of resistance to imatinib which is not associated with secondary mutations. This emphasizes the presence of mechanisms of resistance other than the receptor-related genotype, and the need of biological predictors to select the optimal therapeutic strategy, particularly now that other potent inhibitors are available. We investigated a panel of 31 polymorphisms in 11 genes, potentially associated with the pharmacogenetics of imatinib, in a group of 54 unresectable/metastatic GISTs treated with imatinib 400 mg daily as first line therapy. Included in this analysis were polymorphisms in the transporters’ family SLC22, SLCO, ABC, and in the metabolizing genes CYP -3A4 and -3A5. Time to progression was significantly improved in presence of the C allele in SLC22A4 (OCTN1 rs1050152), and the two minor alleles (G) in SLC22A5 (OCTN2 rs2631367 and rs2631372). Importantly, multivariate analysis, adjusting for age, gender, KIT/PDGFRα mutational status, and tumour size, revealed that all the three genotypes maintained independent predictive significance. In conclusion, in this study we showed that SLC22A4 and SLC22A5 genotypes may be an important predictor of time to progression in GIST patients receiving imatinib therapy. Further investigations are required in an attempt to further personalize GIST therapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
